CLAIMS

1. A combination comprising:
   - one or more mRNA molecules encoding CD40L, caTLR4 and CD70; and
   - one or more mRNA molecules encoding a tumor-associated antigen;
   for use in the treatment of metastatic cancer patients with stable disease as best objective response after first line checkpoint inhibitor therapy.

2. The combination for use as defined in claim 1, in combination with a check point inhibitor therapy.

3. The combination for use as defined in anyone of claims 1 to 2; wherein said tumor-associated antigen is a melanoma antigen, preferably selected from the list comprising: tyrosinase, glycoprotein 100 (gp100), melanoma-associated antigen A3 (MAGE A3), melanoma-associated antigen C2 (MAGE C2) preferentially expressed antigen in melanoma (PRAME) and New York esophageal squamous cell carcinoma 1 (NY-ESO-1).

4. The combination for use as defined in anyone of claims 1 to 3; in the treatment of metastatic cancer patients with stable disease as best objective response after at least 6 months of first line checkpoint inhibitor therapy.

5. The combination for use as defined in anyone of claims 1 to 4; wherein said checkpoint inhibitor therapy is selected from anti-PD-1 therapy and anti-CTLA4 therapy; preferably anti-PD-1 therapy.

6. The combination for use as defined in claim 5; wherein said anti-PD-1 therapy is an antagonistic antibody directed against PD-1, such as selected from the list comprising: nivolumab (BMS-936558/MDX1106), pidilizumab (CT-011) and pembrolizumab (MK-3475); preferably pembrolizumab (MK-3475).

7. The combination for use as defined in anyone of claims 1 to 6; wherein said one or more mRNA molecules are formulated for parenteral administration; more in particular for intravenous, intratumoral, intradermal, subcutaneous, intraperitoneal, intramuscular or intranodal administration; preferably intranodal administration.

8. A combination comprising:
- mRNA molecules encoding CD40L, caTLR4 and CD70; and
- mRNA molecules encoding tyrosinase, glycoprotein 100 (gp100), melanoma-associated antigen A3 (MAGE A3), melanoma-associated antigen C2 (MAGE C2) and preferentially expressed antigen in melanoma (PRAME);

in combination with pembrolizumab;

for use in the treatment of a metastatic cancer patient by means of intranodal administration, wherein said patient is diagnosed with stable disease as best objective response after 6 months of first line pembrolizumab therapy.

9. A combination comprising:
- mRNA molecules encoding CD40L, caTLR4 and CD70; and
- mRNA molecules encoding tyrosinase, glycoprotein 100 (gp100), melanoma-associated antigen A3 (MAGE A3), melanoma-associated antigen C2 (MAGE C2) and and New York esophageal squamous cell carcinoma 1 (NY-ESO-1);

in combination with pembrolizumab;

for use in the treatment of a metastatic cancer patient by means of intranodal administration, wherein said patient is diagnosed with stable disease as best objective response after 6 months of first line pembrolizumab therapy.

10. The combination for use as defined in anyone of claims 1 to 9; wherein said combination is administered according to the following administration scheme:
- administrations 1-5: with an interval of about 1 week each;
- administration 6: about 2 weeks after administration 5;
- administration 7: about 3 weeks after administration 6;
- administration 8: about 6 weeks after administration 7;
- administration 9: about 6 weeks after administration 8.

11. The combination for use as defined in anyone of claims 2 to 9; wherein said combination is administered according to the following administration scheme:
- administrations 1-5: with an interval of about 1 week each;
- administration 6: about 2 weeks after administration 5;
- administration 7: about 3 weeks after administration 6;
- administration 8: about 6 weeks after administration 7;
- administration 9: about 6 weeks after administration 8;

and wherein said check point inhibitor therapy is administered at the same day of said combination prior, simultaneously or after administrations 1, 4, 6, 7, 8 and 9.

12. The combination for use as defined in claim 11; wherein said check point inhibitor therapy is additionally administered between administrations 7 and 8; and between administrations 8 and 9.

13. The combination for use as defined in anyone of claims 1-12; wherein said combination comprises:

- about 300 μg mRNA encoding CD40L;
- about 300 μg mRNA encoding caTLR4;
- about 300 μg mRNA encoding CD70;
- about 900 μg mRNA encoding tumor-associated antigen(s)

14. The combination for use as defined in anyone of claims 1-12; wherein said combination comprises:

- about 600 μg mRNA encoding CD40L;
- about 600 μg mRNA encoding caTLR4;
- about 600 μg mRNA encoding CD70;
- about 1800 μg mRNA encoding tumor-associated antigen(s)